3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
2
Breast Neoplasms
2
Vascular Diseases
1
Rectal Neoplasms
1
Precancerous Conditions
1
Neurotoxicity Syndromes
1
Myocardial Ischemia
1
Myocardial Infarction
1
Heart Diseases
1
Fibrosis
1
Fatigue
1
Erectile Dysfunction
1
Coronary Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cerebrovascular Disorders
1
Cardiovascular Diseases
1
Brain Neoplasms
1
Adenomatous Polyps
1
Interventions
Bevacizumab
112
Fluorouracil
98
Oxaliplatin
96
Leucovorin
96
Irinotecan
86
Capecitabine
73
Cetuximab
64
Panitumumab
42
pembrolizumab
38
regorafenib
28
Nivolumab
23
IFL protocol
22
Folfox protocol
21
trifluridine tipiracil drug combination
14
Radiotherapy
13
durvalumab
11
Gemcitabine
10
Celecoxib
10
tremelimumab
7
binimetinib
7
aflibercept
7
Drug Therapy
7
Disulfides
7
Cyclophosphamide
7
Trifluridine
6
Trastuzumab
6
Sunitinib
6
Paclitaxel
6
Immunoglobulin G
6
Colonoscopy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Colorectal Neoplasms
×
Vitamin E
×
Clear all
NCT00706121
2019-12-16
ACP
SWOG Cancer Research Network
Phase 3
Completed
8,094 enrolled
23 charts